凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688065 凯赛生物

等待开盘 11-20 09:30:00

{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":46.65,"timestamp":1732066135000,"preClose":46.65,"halted":0,"volume":2500,"delay":0,"floatShares":583000000,"shares":583000000,"eps":0.682,"marketStatus":"等待开盘","marketStatusCode":7,"change":0,"latestTime":"11-20 09:30:00","open":46.65,"high":46.65,"low":46.65,"amount":116600,"amplitude":0,"askPrice":46.98,"askSize":10,"bidPrice":46.65,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.682,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":46.65,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732066200000,1732073400000],[1732078800000,1732086000000]],"highLimit":51.32,"lowLimit":41.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":583378039,"pbRate":2.39,"roa":"--","roe":"3.04%","epsLYR":0.63,"committee":-0.012048,"marketValue":27215000000,"floatMarketCap":27215000000,"peRate":68.401761,"changeRate":0,"turnoverRate":0,"status":2},"requestUrl":"/m/hq/s/688065/wiki","defaultTab":"wiki","newsList":[{"id":"2483553574","title":"凯赛生物（688065）11月15日主力资金净卖出2600.17万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483553574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483553574?lang=zh_cn&edition=full","pubTime":"2024-11-16 08:24","pubTimestamp":1731716660,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月15日收盘，凯赛生物报收于46.81元，下跌5.34%，换手率0.73%，成交量4.26万手，成交额2.04亿元。近5日资金流向一览见下表：凯赛生物融资融券信息显示，融资方面，当日融资买入2022.21万元，融资偿还4962.35万元，融资净偿还2940.14万元。凯赛生物主营业务：利用生物制造技术,从事新型生物基材料的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111600014554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"gpt_icon":0},{"id":"2483997003","title":"上海证券：给予凯赛生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2483997003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483997003?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:56","pubTimestamp":1731642998,"startTime":"0","endTime":"0","summary":"上海证券有限责任公司于庭泽,王真真近期对凯赛生物进行研究并发布了研究报告《凯赛生物2024三季报点评：三季报业绩改善，生物基新材料打开应用空间》，本报告对凯赛生物给出买入评级，当前股价为48.06元。　　公司定向增发通过上交所审核，与招商局合作取得实质性进展　　11月8日，公司收到上海证券交易所上市审核中心出具的《关于上海凯赛生物技术股份有限公司向特定对象发行股票审核意见的通知》。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500016824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688065"],"gpt_icon":0},{"id":"2483439697","title":"上海证券给予凯赛生物买入评级：三季报业绩改善，生物基新材料打开应用空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2483439697","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483439697?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:31","pubTimestamp":1731641479,"startTime":"0","endTime":"0","summary":"上海证券11月14日发布研报称，给予凯赛生物（688065.SH，最新价：47.99元）买入评级。评级理由主要包括：1）癸二酸产能放量带动业绩增长，并持续加大研发投入；2）公司定向增发通过上交所审核，与招商局合作取得实质性进展；3）作为生物基新材料领域的领先企业，公司在多个展会上展示新成果。风险提示：放大量产不及预期的风险、新品市场验证不及预期的风险、原材料和能源价格波动风险、下游客户拓展不及预期的风险、产能建设不及预期的风险。AI点评：凯赛生物近一个月获得1份券商研报关注，买入1家。文章来源：每日经济新闻原标题：上海证券给予凯赛生物买入评级：三季报业绩改善，生物基新材料打开应用空间","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115113925abc30b75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115113925abc30b75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159703","161027","688065"],"gpt_icon":0},{"id":"2483361259","title":"凯赛生物癸二酸产能放量，Q3盈利同比增幅明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2483361259","media":"国海证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483361259?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:17","pubTimestamp":1731633439,"startTime":"0","endTime":"0","summary":"投资要点：癸二酸产能放量，2024Q3盈利同比大幅上升2024年前三季度公司实现营业收入22.15亿元，同比+41.49%；实现归母净利润3.45亿元，同比+9.97%；实现扣非归母净利润3.35亿元，同比+25.51%；销售毛利率32.20%，同比+3.72个pct，销售净利率15.28%，同比-7.29个pct；经营活动现金流净额为6.76亿元，同比+27.48%。2024Q3公司归母净利润同比上升，主要由于新产品癸二酸产能放量，长链二元酸销售量、销售收入较去年同期大幅上涨，带动公司整体净利润大幅上涨。2024Q3公司毛利润同比增长1.23亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115092732abc2a49d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115092732abc2a49d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208"],"gpt_icon":0},{"id":"2483846570","title":"凯赛生物11月14日遭主力抛售3433万元 环比增加323.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483846570","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483846570?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:20","pubTimestamp":1731568823,"startTime":"0","endTime":"0","summary":"11月14日, 凯赛生物股价跌4.41%，报收49.45元，成交金额1.96亿元，换手率0.67%，振幅6.19%，量比0.64。凯赛生物今日主力资金净流出3433万元，上一交易日主力净流出811万元，今日环比增加323.30%。该股近5个交易日上涨2.70%，主力资金累计净流入8436万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.00亿元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114153907abc01c5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114153907abc01c5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208"],"gpt_icon":0},{"id":"2483810039","title":"凯赛生物大跌5.28% 4家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483810039","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483810039?lang=zh_cn&edition=full","pubTime":"2024-11-14 14:52","pubTimestamp":1731567137,"startTime":"0","endTime":"0","summary":"11月14日，凯赛生物股价大幅下跌，截至14点52分，凯赛生物下跌5.28%，报49.00元/股，失守50元整数关口，成交1.79亿元，换手率0.61%。此外，数据统计显示，近半年内4家券商给予增持建议，5家券商给予买入建议。资金动向截止发稿，凯赛生物获得主力净流出2946万元，其中超大单流出1748万元，大单流出1197万元。最新财报显示，今年三季报，凯赛生物实现营业收入22.15亿元，同比增长41.49%，净利润为3.45亿元，同比增长9.97%，基本每股收益为0.59元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114145236abbff02e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114145236abbff02e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","688065"],"gpt_icon":0},{"id":"2482214257","title":"凯赛生物11月12日主力资金流入418万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2482214257","media":"市场透视","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482214257?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:22","pubTimestamp":1731396151,"startTime":"0","endTime":"0","summary":"11月12日, 凯赛生物股价跌2.84%，报收52.01元，成交金额3.23亿元，换手率1.04%，振幅6.87%，量比0.97。凯赛生物今日主力资金净流入418万元，连续5日净流入，上一交易日主力净流入4112万元，今日环比减少89.83%。该股近5个交易日上涨8.58%，主力资金累计净流入1.48亿元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2.27亿元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155753a22f91d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155753a22f91d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","688065"],"gpt_icon":0},{"id":"2482115279","title":"11月11日凯赛生物涨6.72%，科创板博时基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482115279","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482115279?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:08","pubTimestamp":1731312536,"startTime":"0","endTime":"0","summary":"证券之星消息，11月11日凯赛生物涨6.72%，收盘报53.53元，换手率1.55%，成交量9.03万手，成交额4.74亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为科创板博时。科创板博时目前规模为11.71亿元，最新净值0.8284，较上一交易日上涨1.68%，近一年上涨3.85%。科创板博时的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100019585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","688065","BK0208"],"gpt_icon":0},{"id":"2482279149","title":"凯赛生物涨6.72%，华安证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2482279149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482279149?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:08","pubTimestamp":1731312528,"startTime":"0","endTime":"0","summary":"今日凯赛生物涨6.72%，收盘报53.53元。2024年11月3日，华安证券研究员王强峰,刘天其发布了对凯赛生物的研报《Q3业绩符合预期，癸二酸持续放量》，该研报对凯赛生物给出“买入”评级。研报中预计公司2024-2026年归母净利润分别为4.73、6.55、8.57亿元，同比增速为29.1%、38.4%、30.8%。对应PE分别为57、42、32倍。维持“买入”评级。凯赛生物个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100019581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","600909"],"gpt_icon":0},{"id":"2482248870","title":"凯赛生物大幅上涨 收到向特定对象发行股票审核意见通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2482248870","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482248870?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:30","pubTimestamp":1731288600,"startTime":"0","endTime":"0","summary":"消息解读凯赛生物11月8日晚间发布公告称，上海凯赛生物技术股份有限公司于 2024 年 11 月 8 日收到上海证券交易所出具的《关于上海凯赛生物技术股份有限公司向特定对象发行股票审核意见的通知》。最新财报显示，今年三季报，凯赛生物实现营业收入22.15亿元，同比增长41.49%，净利润为3.45亿元，同比增长9.97%，基本每股收益为0.59元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111094605abb4479d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111094605abb4479d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208"],"gpt_icon":0},{"id":"2481712376","title":"凯赛生物(688065.SH)向特定对象发行A股股票申请获上交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2481712376","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481712376?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:39","pubTimestamp":1731058752,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯赛生物(688065.SH)发布公告，公司于2024年11月8日收到上交所出具的《关于上海凯赛生物技术股份有限公司向特定对象发行股票审核意见的通知》：“上海凯赛生物技术股份有限公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。本所将在履行相关程序并收到你公司申请文件后提交中国证监会注册。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399300","BK0208","688065","159982"],"gpt_icon":0},{"id":"2481128025","title":"凯赛生物：非公开发行股票申请获得上交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2481128025","media":"每日经济新闻","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481128025?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:31","pubTimestamp":1731058272,"startTime":"0","endTime":"0","summary":"每经AI快讯，凯赛生物11月8日晚间发布公告称，上海凯赛生物技术股份有限公司 于 2024 年 11 月 8 日收到上海证券交易所出具的《关于上海凯赛生物技术股份有限公司向特定对象发行股票审核意见的通知》。本所将在履行相关程序并收到你公司申请文件后提交中国证监会注册。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108173143a223d20b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108173143a223d20b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","688065"],"gpt_icon":0},{"id":"2481122128","title":"凯赛生物最新公告：向特定对象发行A股股票申请获得上交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2481122128","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481122128?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:21","pubTimestamp":1731057690,"startTime":"0","endTime":"0","summary":"凯赛生物公告，公司向特定对象发行A股股票申请已获上交所审核通过，符合发行条件、上市条件和信息披露要求。上交所将在履行相关程序并收到公司申请文件后提交中国证监会注册。本次发行事项尚需获得中国证监会同意注册的决定后方可实施，最终能否获得同意注册的决定及其时间尚存在不确定性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800028804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","688065","159982","BK0208"],"gpt_icon":0},{"id":"2481161994","title":"凯赛生物大幅上涨 获主力净流入761万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481161994","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481161994?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:32","pubTimestamp":1731029554,"startTime":"0","endTime":"0","summary":"资金动向截止发稿，凯赛生物获得主力净流入761万元，其中超大单流入822万元，大单流出60万元。融资融券方面，凯赛生物11月06日获得融资净买入572万元，当日该股融资余额为4.57亿元，当较前一日增加1.27%，实现3连增；该股融券余额为297万元，融券余量为5.89万股，比上日减少9.58%。最新财报显示，今年三季报，凯赛生物实现营业收入22.15亿元，同比增长41.49%，净利润为3.45亿元，同比增长9.97%，基本每股收益为0.59元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093532ababa6c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093532ababa6c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208"],"gpt_icon":0},{"id":"2481479255","title":"凯赛生物11月05日主力资金流出460万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2481479255","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481479255?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:18","pubTimestamp":1730791084,"startTime":"0","endTime":"0","summary":"11月05日, 凯赛生物股价涨0.65%，报收47.90元，成交金额2.37亿元，换手率0.85%，振幅3.78%，量比1.20。凯赛生物今日主力资金净流出460万元，连续3日净流出，上一交易日主力净流出1952万元，今日环比减少76.43%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为52.38%，平均跌幅为1.43%。该股近5个交易日上涨2.35%，主力资金累计净流出2459万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4967万元，其中净流入天数为9日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105152617aba105f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105152617aba105f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","688065"],"gpt_icon":0},{"id":"2480303063","title":"凯赛生物：Q3业绩受费用影响环比承压 生物基复材商业化稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2480303063","media":"申万宏源研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480303063?lang=zh_cn&edition=full","pubTime":"2024-11-04 00:00","pubTimestamp":1730649600,"startTime":"0","endTime":"0","summary":"24Q3 公司生物法二元酸业务延续上半年良好状态，但受费用端影响利润环比短期承压。24Q3 单季度，公司整体销售维持24H1 的良好表现，营收环比仍有小幅恢复，单由于受到财务费用、研发费用的短期影响，利润端环比承压。2023 年公司公告拟定增募集不超过66 亿元并引入招商局集团作为间接股东并与其达成合作协议，共同开拓生物基聚酰胺复合材料产品在新能源装备、现代物流、绿色建筑等行业的应用落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411041901229f591ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411041901229f591ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208"],"gpt_icon":0},{"id":"2480354366","title":"华安证券：给予凯赛生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480354366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480354366?lang=zh_cn&edition=full","pubTime":"2024-11-03 17:51","pubTimestamp":1730627477,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司王强峰,刘天其近期对凯赛生物进行研究并发布了研究报告《Q3业绩符合预期，癸二酸持续放量》，本报告对凯赛生物给出买入评级，当前股价为46.61元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级3家，增持评级3家；过去90天内机构目标均价为58.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300001494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","600909"],"gpt_icon":0},{"id":"2480323352","title":"凯赛生物：Q3业绩符合预期 癸二酸持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2480323352","media":"华安证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480323352?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563200,"startTime":"0","endTime":"0","summary":"事件描述2024 年10 月30 日，凯赛生物发布了2024 年三季报。公司2024Q3 实现营业收入为7.71 亿元，同比上涨44.06%，环比上涨1.45%；归母净利润为0.98 亿元，同比上涨35.69%，环比下降31.27%；扣非净利润为0.96，同比上涨84.38%，环比下降30.10%。第三季度营业收入创历史新高，业绩环比略有承压癸二酸放量带动营收增长，业绩受汇率波动略有承压。公司新产品癸二酸放量，长链二元酸销量较去年同期大幅上涨所致。受汇兑收益波动影响，业绩环比小幅下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411031806339f591193&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411031806339f591193&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208"],"gpt_icon":0},{"id":"2480047758","title":"凯赛生物2024年三季报点评：立足研发创新 二元酸产销增加驱动前三季度业绩上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2480047758","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480047758?lang=zh_cn&edition=full","pubTime":"2024-11-01 00:00","pubTimestamp":1730390400,"startTime":"0","endTime":"0","summary":"2024 年前三季度公司营业收入及毛利率持续环比向上，主要得益于公司加大研发投入、市场开拓和新产品销售力度，同时新产品癸二酸产能放量，并带动长链二元酸销售量及销售收入较去年同期大幅上涨。立足技术创新，研发费用持续增加。研发和创新是生物制造及复合材料产业发展的基础，公司在报告期内继续加大研发投入，2024 年前三季度投入研发费用1.69 亿元，同比+33.52%，研发费用率高达7.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110113012895bda5b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110113012895bda5b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","688065"],"gpt_icon":0},{"id":"2479774511","title":"凯赛生物(688065)9月30日股东户数0.96万户，较上期减少1.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479774511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479774511?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:10","pubTimestamp":1730365837,"startTime":"0","endTime":"0","summary":"证券之星消息，近日凯赛生物披露，截至2024年9月30日公司股东户数为9569.0户，较6月30日减少181.0户，减幅为1.86%。在化学制品行业个股中，凯赛生物股东户数低于行业平均水平，截至9月30日，化学制品行业平均股东户数为2.47万户。从股价来看，2024年6月30日至2024年9月30日，凯赛生物区间涨幅为5.24%，在此期间股东户数减少181.0户，减幅为1.86%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100033748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","stockEarnings":[{"period":"1week","weight":-0.1031},{"period":"1month","weight":0.013},{"period":"3month","weight":0.353},{"period":"6month","weight":-0.0409},{"period":"1year","weight":-0.0937},{"period":"ytd","weight":-0.1474}],"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","perCapita":"60965股","boardName":"化学纤维制造业","registeredCapital":"58337万元","compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":0.0259},{"period":"3month","weight":0.1713},{"period":"6month","weight":0.0737},{"period":"1year","weight":0.0905},{"period":"ytd","weight":0.1247}],"survey":"　　上海凯赛生物技术股份有限公司从事新型生物基材料的研发、生产及销售。公司目前主要产品为生物法长链二元酸系列产品、生物基聚酰胺及单体产品等。公司重视打造技术竞争力，坚持走自主创新的发展道路，截至报告期末公司拥有318项发明专利在内的406项专利，获得国际纺织制造商联合会（ITMF）颁发的“《可持续与创新奖》（SUSTAINABILITY&INNOVATION）”，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”。","serverTime":1732066153338,"listedPrice":133.45,"stockholders":"9569人(较上一季度减少1.86%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}